scholarly journals Invasive adenocarcinoma of the prostate mimicking transitional cell carcinoma in urinary cytology. Report of case.

1996 ◽  
Vol 35 (3) ◽  
pp. 257-261
Author(s):  
Takaki SAKURAI ◽  
Mitsuyosi HIROKAWA ◽  
Yoshiki MIKAMI ◽  
Takashi FUKUYA ◽  
Sakae HATA ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Urinary Cytology ◽  
Invasive Adenocarcinoma ◽  
Adenocarcinoma Of The Prostate ◽  
Cytology Report

847: Institutional Variability in Predictive Accuracy of Urinary Cytology for Prediction of Transitional Cell Carcinoma Recurrence

2005 ◽  
Vol 173 (4S) ◽  
pp. 230-230
Author(s):  
Serge Benayoun ◽  
Shahrokh F. Shariat ◽  
Paul Perrotte ◽  
Martin G. Friedrich ◽  
Craig D. Zippe ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Predictive Accuracy ◽  
Transitional Cell ◽  
Urinary Cytology

Intra vesical gemcitabine (G) single agent as adjuvant chemotherapy in superficial transitional cell carcinoma (TCC) of the bladder: Final results

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5078-5078
Author(s):  
A. Bounedjar ◽  
R. Ferhat ◽  
F. Smaili ◽  
K. Bouzid
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Bladder Carcinoma ◽  
Performance Status ◽  
Single Agent ◽  
Transitional Cell ◽  
Hot Flashes ◽  
Haematological Toxicity ◽  
Urinary Cytology ◽  
Bcg Therapy

5078 Background: Systemic intravenous G is usually used in advanced bladder carcinoma. A phase I study of intravesical G has shown safety profile in pts refractory to BCG therapy (Dalbani G et al JCO 2002; 20:3193–98). In this study we evaluate the toxicity and the efficacy of intravesical G in patients (pts) with superficial bladder carcinoma. Methods: The study population criteria were: age = 18 years old, histological diagnosis of transitional cell carcinoma (TCC) of bladder (Cis and pT1) confirmed by transurethral resection (TUR), no prior chemotherapy, a performance status (PS) < 2, good bone marrow reserve, adequate renal and liver function and informed consent. Three weeks after a total TUR, pts receive intravesical instillation of 2,000 mg G every wk for 6 wks, than every month for six months. Evaluation is performed 3–4 wks after the last instillation (CT scan and/or US pelvis, urinary cytology and cystoscopy with biopsy). Results: From February 2003 to June 2004, 60 pts (57M/3F) were enrolled in the study (M/F = 57/3). The median age was 59,5 years old (24–84). Nine pts had a carcinoma in situ (Cis) and 51 had pT1 lesions. They received a total of 720 instillations. All pts were evaluable for toxicity and response Toxicity (CTC/NCI scale) is evaluated over the 720 instillations. Non haematological toxicity was grade 1: irritate bladder reaction (4.7%), asthenia (2.9%), nausea and vomiting (1.8%) and hot flashes (2%). Grade 1 haematological toxicity: anaemia (6.8%), leucopenia (4.5%) and thrombocytopenia (0.4%). After a follow-up time of 30 to 48 months, all pts were evaluable for tumor response: 53 patient had a persistant complete remission after TUR. Five patients (8.3%) had a superficial relapse of TCC (one at six months, 2 at 9 months and 2 others at 12 months). Two patients had progressive disease at 18 months and 27 months. Conclusion: Intravesical G is an active and well tolerated treatment even after repeated instillation in pts with superficial TCC carcinoma of the bladder. No significant financial relationships to disclose.

Clinical evaluation of nuclear matrix protein 22 as urinary marker of transitional cell carcinoma of bladder

2008 ◽  
Vol 75 (1) ◽  
pp. 20-23
Author(s):  
R.F. Liotta ◽  
F. Mangiapia ◽  
M.L. Tarantino ◽  
S. Di Meo ◽  
V. Mirone ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Tumor Marker ◽  
Cell Carcinoma ◽  
Nuclear Matrix ◽  
Matrix Protein ◽  
Transitional Cell ◽  
Cancer Surveillance ◽  
Urinary Cytology ◽  
Nuclear Matrix Protein

Objectives. Biomarkers (BTA, NMP22, FDP etc.) have been and continue to be evaluated as adjuncts or substitutes for cystoscopy, which is invasive and uncomfortable for some patients. Nuclear matrix protein-22 (NMP22) is involved in the regulation of nuclear processes. The main objective of the present study is to evaluate the clinical utility of urinary NMP22 as a tumor marker in the follow-up of transitional cell carcinoma (TCC) of the bladder. Materials and Methods. The study included 62 patients undergoing follow-up, who had had TCC of bladder but who were disease-free at the beginning of the study, as confirmed by cystoscopy. Urine samples were collected for urinary cytology and NMP22 test before the cystoscopy. All samples were processed according to the instructions provided with the manufacturer's kit instructions. Results. 12 cases of TCC recurrences were detected with biopsy. Cystoscopy was positive in 8 cases, NMP22 test was positive in 11 cases, and in only one case the cytopathology yielded positive results. In 14 cases NMP22 resulted as false positive. Conclusions. Urinary NMP22 appeared to be a potential tumor marker for detecting TCC of the bladder, which might rise the sensitivity of cystoscopy especially in high-grade cancer surveillance more than cytology might do.

Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder

2006 ◽  
Vol 97 (5) ◽  
pp. 997-1001 ◽  
Author(s):  
PIERRE I. KARAKIEWICZ ◽  
SERGE BENAYOUN ◽  
CRAIG ZIPPE ◽  
GERSON LUDECKE ◽  
HANS BOMAN ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Urinary Cytology ◽  
Carcinoma Of The Bladder

Radioimmunoassay of creatine kinase B-isoenzymes in serum of patients with azotemia, obstructive uropathy, or carcinoma of the prostate or bladder.

1980 ◽  
Vol 26 (13) ◽  
pp. 1821-1824 ◽  
Author(s):  
H A Homburger ◽  
S A Miller ◽  
G L Jacob
Keyword(s):  
Renal Failure ◽  
Creatine Kinase ◽  
Benign Prostatic Hyperplasia ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Prostatic Hyperplasia ◽  
Creatine Kinase B ◽  
Adenocarcinoma Of The Prostate ◽  
Carcinoma Of The Bladder

Abstract We measured the concentrations of creatine kinase B-isoenzymes by radioimmunoassay in 271 serum specimens from patients with azotemia, benign prostatic hyperplasia, adenocarcinoma of the prostate, and transitional cell carcinoma of the bladder. There was no correlation between the concentrations of B-isoenzymes and creatinine in the sera of azotemic patients. Above-normal concentrations of B-isoenzymes were found in sera from three patients with acute renal failure, but in only two of 28 specimens from patients with chronic renal failure. Above-normal concentrations of B-isoenzymes also were found in sera from three of 18 patients with untreated carcinoma of the prostate, 10 of 25 patients with treated carcinoma, 20 of 135 patients with benign prostatic hyperplasia, and 10 of 33 patients and with transitional cell carcinoma of the bladder. An above-normal concentration of B-isoenzymes in serum has a low predictive value for adenocarcinoma of the prostate, was not a sensitive indicator of the presence of carcinoma, and was noted paradoxically in six patients with treated carcinoma who had normal acid phosphatase activities in serum. We conclude that routine measurement of B-isoenzymes is not useful to establish the diagnosis of adenocarcinoma of the prostate.

Preliminary comparative considerations about urinary cytology and the Bard BTA test in the diagnosis and follow-up of superficial bladder cancer

1995 ◽  
Vol 62 (1_suppl) ◽  
pp. 88-90
Author(s):  
C. Boccafoschi ◽  
F. Montefiore ◽  
S. Treffiletti ◽  
D. Signorello ◽  
A. Langé
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Bladder Tumour ◽  
Transitional Cell ◽  
Latex Agglutination ◽  
Urinary Cytology ◽  
In Vitro Test ◽  
Carcinoma Of The Bladder

— The value of urinary cytology in the diagnosis and follow-up of superficial transitional cell carcinoma of the bladder is well known. Results of traditional cytologic examinations may be affected by the different methods of urine collection, preservation, manipulation and observation of the samples so that more objective tools are desirable. The aim of this study in to compare the traditional cytologic examinations with a new diagnostic in-vitro test (Bard BTA test), which can detect antigen complexes in the urine due to the contact of the tumour cells with the basement membrane. The Bard BTA test is a latex agglutination assay which identifies the bladder tumour antigens in the urine. The result of the agglutination reaction (positive or negative) may be visually distinguished by the variation in colour of special strips of testing paper. The Authors report on a preliminary experience in the follow-up of patients with previous superficial transitional cell carcinoma of the bladder: they compare the results of traditional cytology, the Bard BTA test and cystoscopy and have found agreement in 70% of the cases.

Sign in / Sign up

Export Citation Format

Share Document